We claim:

A compound of the formula (I):

wherein

R₁, R₂, R₃, and R₄ are, independently of one another, alkyl residues with 1 to 6 carbon atoms;

or a physiologically tolerated salt thereof,

or a derivative thereof,

or a stereoisomeric form of:

a compound of formula (I) às described above,

or a physiologically tolerated salt of a compound of formula (I) as described above,

or a derivative of a compound of formula (I) as described above or a tautomeric form of:

a compound of formula (I) as described above,

or a physiologically tolerated salt of a compound of formula (I) as described above.

or a derivative of a compound of formula (I) a's described above.

FINNEGAN, HENDERSON, FARABOW, GARRETT, & DUNNER, L. L. P. 1300 I STREET, N. W.

WAS HINGTON, DC 20005 202-408-4000

LAW OFFICES

2. The compound of formula (I) as claimed in claim 1, wherein one, two, three, or all of R₁ to R₄ are butyl residues, and wherein any of the butyl residues may be straight-chain or branched,

or a physiòlogically tolerated salt thereof,

or a derivative thereof,

or a stereoisomeric form of:

the compound of formula (I) as described above in this claim, or a physiologically tolerated salt of the compound of formula (I) as described above in this claim,

or a derivative of the compound of formula (I) as described above in this claim,

or a tautomeric form δf:

the compound of formula (I) as described above in this claim, or a physiologically tolerated salt of the compound of formula (I) as described above in this claim,

or a derivative of the compound of formula (I) as described above in this claim.

3. The compound of formula (I) as claimed in claim 1, wherein R₁ to R₄ comprise three butyl residues and one propyl residue, and wherein any of the alkyl residues may be straight-chain or branched,

or a physiologically tolerated salt thereof,

or a derivative thereof,

or a stereoisomeric form of:

the compound of formula (I) as described above in this claim, or a physiologically tolerated salt of the compound of formula (I) as described above in this claim,

or a derivative of the compound of formula (I) as described above in this claim.

or a tautomèric form of:

this claim.

the compound of formula (I) as described above in this claim, or a physiologically tolerated salt of the compound of formula (I) as described above in this claim, or a derivative of the compound of formula (I) as described above in

4. The compound of formula (I) as claimed in claim 1, wherein R₁ to R₄ comprise: two butyl and two propyl residues, or one butyl, one pentyl, one ethyl, and one propyl residue, and wherein any of the alkyl residues may be straight-chain or branched,

or a physiologically tolerated salt thereof,

or a derivative thereof.

or a stereoisomeric form of:

the compound of formula (I) as described above in this claim, or a physiologically tolerated salt of the compound of formula (I) as described above in this claim,

or a derivative of the compound of formula (I) as described above in this claim,

or a tautomeric form of:

the compound of formula (I) as described above in this claim, or a physiologically tolerated salt of the compound of formula (I) as described above in this claim, or a derivative of the compound of formula (I) as described above in this claim.

5. The compound of formula (I) as claimed in claim 1, wherein R₁ to R₄ comprise four butyl residues or two butyl, one propyl and one pentyl residue, and wherein any of the alkyl residues may be straight-chain or branched, or a physiologically tolerated salt thereof,

or a derivative thereof,

or a stereoisomeric form of:

the compound of formula (I) as described above in this claim, or a physiologically tolerated salt of the compound of formula (I) as described above in this claim,

or a derivative of the compound of formula (I) as described above in this claim.

or a tautomeric form of:

the compound of formula (I) as described above in this claim, or a physiologically tolerated salt of the compound of formula (I) as described above in this claim,

or a derivative of the compound of formula (I) as described above in this claim.

- 6. A mixture comprising two or more isomers of a compound of formula (I) as claimed in claim 1.
- 7. A mixture comprising two or more isomers of a compound of formula (I) as claimed in claim 2.
- 8. A mixture comprising two or more isomers of a compound of formula (I) as claimed in claim 3.
- 9. A mixture comprising two or more isomers of a compound of formula (I) as claimed in claim 4.
- 10. A mixture comprising two or more isomers of a compound of formula (I) as claimed in claim 5.

- A compound of the formula (I), or a physiologically tolerated salt or derivative thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 1, obtainable by cultivation of Streptomycete sp. ST 101396 (DSM 13309) or by cultivation of one of the variants or mutants of DSM 13309.
- 12. A compound of the formula (I), or a physiologically tolerated salt or derivative thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 2, obtainable by cultivation of Streptomycete sp. ST 101396 (DSM 13309) or by cultivation of one of the variants or mutants of DSM 13309.
- 13. A compound of the formula (I), or a physiologically tolerated salt or derivative thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 3, obtainable by cultivation of Streptomycete sp. ST 101396 (DSM 13309) or by cultivation of one of the variants or mutants of DSM 13309.
- 14. A compound of the formula (I), of a physiologically tolerated salt or derivative thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 4, obtainable by cultivation of Streptomycete sp. ST 101396 (DSM 13309) or by cultivation of one of the variants or mutants of DSM 13309.
- 15. A compound of the formula (I), or a physiologically tolerated salt or derivative thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 5, obtainable by cultivation of Streptomycete sp. ST 101396 (DSM 13309) or by cultivation of one of the variants or mutants of DSM 13309.
- 16. A process for the production of a compound of formula (I), or a salt or a derivative thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 1, comprising

cultivating Streptomycete sp. ST 101396 (DSM 13309) or one of its variants or mutants,

isolating and purifying one or more target compounds, and optionally converting said target compound into a physiologically tolerated sait or derivative.

- 17. The process as claimed in claim 16, wherein the cultivation is carried out at a temperature in the range between about 20°C and about 35°C and a pH in the range between about 5 and about 8.
- 18. A pharmaceutical composition comprising an effective amount of at least one compound of formula (I), or a physiologically tolerated salt or derivative thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 1, and a pharmaceutically acceptable carrier.
- 19. A method for reducing the activity of a neurotensin receptor comprising administering to a patient in need thereof at least one compound of formula (I), or a physiologically tolerated salt or derivative thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 1.
- 20. A method for treating a disease comprising administering to a patient in need thereof at least one compound of formula (I), or a physiologically tolerated salt or derivative thereof, or a stereoisomer or a tautomer thereof, as claimed in claim 1, wherein the disease is chosen from schizophrenia, Parkinson's disease, and Alzheimer's disease.
- 21. A method for the production of a pharmaceutical composition, comprising mixing at least one compound of formula (I), or a physiologically tolerated salt or derivative thereof, or a stereoisomer or a tautomer thereof, as claimed in



claim 1, and suitable excipients and/or carriers, and converting the mixture into a suitable dosage form.

22. Streptomycetes species ST 101396 (DSM 13309).